Breast cancer treatment approved for NHS use
Six new drugs, including a treatment for patients with advanced breast cancer, have been approved for use by the NHS in ...
labiotech1h
Monoclonal antibodies: are they the key to treating Alzheimer’s disease?
Explore the potential of monoclonal antibodies in Alzheimer’s treatment, including breakthroughs and challenges in this ...
Drug proven to slow Alzheimer's won't be given to Scots NHS patients
The first drug proven to slow down Alzheimer's won't be available to dementia patients in Scotland - unless they pay £60,000 ...
Little known 'third' type of diabetes linked to Alzheimer's disease
There isn't a cure for the condition, but doctors may recommend medications to slow down the progression of the disease or ...
First drug proven to slow Alzheimer's disease won't be given to NHS patients in Scotland after advisors rule it out
The first drug proven to slow down Alzheimer's won't be available to dementia patients in Scotland - unless they pay £60,000 ...
Rolling Out19h
Alzheimer’s drug prevents brain cell damage in medical
Scientists develop groundbreaking dual-action drug RI-AG03 that targets toxic tau proteins in Alzheimer's disease, showing ...
How greed and profit fueled one failed Alzheimer drug
Matt Price drove his 73-year-old father Stephen from their New Jersey home to a medical strip mall on the Jersey Shore, for his first injection of an experimental drug called ...
What to know about sleeping pills and dementia
Are concerns about sleeping pills being linked to dementia based on evidence? Many people need help getting to, or staying, ...
Knowridge1d
These common medicines may affect memory, study finds
As people age, some memory decline is normal. However, if a common medicine speeds up this process, it becomes a serious ...
Mayo Clinic program offered in Eden Prairie can benefit those with early cognitive impairment and early stages of Alzheimer’s disease
BY KARLA WENNERSTROM [email protected] Vern Pennie of Marine on St. Croix points to the list of items to be done and checked off today in his datebook, where he is also making note of ...
No-Moat Lundbeck's Strategic Brands Drive Growth but Face Generic Pressure Amid Patent Losses
However, we still see areas of weakness in the portfolio, including upcoming patent losses and a highly uncertain pipeline due to the complexities of running CNS trials. Historically, the firm ...